NIKKEI 225
39,048.63 +431.53 (+1.12%) HANG SENG
18,853.46 -342.14 (-1.78%) CRUDE OIL
76.93 -0.64 (-0.83%) GOLD FUTURES
2,366.00 -26.90 (-1.12%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,538.58 -370.32 (-0.67%)
Arrowhead Pharmaceuticals, Inc. (ARWR)
After hours:
| Previous close | 25.02 |
| Open | 24.95 |
| Bid | 25.13 x 100 |
| Ask | 25.19 x 100 |
| Day's range | 24.89 - 26.09 |
| 52-week range | 20.67 - 39.83 |
| Volume | |
| Avg. volume | 1,189,141 |
| Market cap | 3.122B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.23 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.77 |
Business WireArrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
PASADENA, Calif., May 20, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar lavage
GuruFocus.comArrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations
Comprehensive Analysis of ARWR's Fiscal 2024 Q2 Earnings Against Market Forecasts
Insider MonkeyArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript May 9, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and […]
